Category: News

News
admin

Lancet Oncology reports safety and efficacy of Holmium-166 SIRT after PRRT

Terumo Europe N.V. and Quirem Medical B.V are proud to share the latest key publication regarding holmium-166 (QuiremSpheres®) Selective Internal Radiation Therapy (SIRT). On 27 February 2020, the UMC Utrecht published their latest results in the Lancet Oncology Journal from the non-randomized HEPAR PLuS study. The study enrolled neuroendocrine tumor

Read More »

Dose-response relation confirmed for Holmium-166 (QuiremSpheres®) SIRT

Quirem Medical is pleased to share that yet another Holmium-166 (QuiremSpheres®) related scientific article has been published, after recently having reported on the publication of Smits et al. on the superior predictive value of 166Ho-Scout (QuiremScout®) compared to 99mTc-MAA as a SIRT work-up. This new, corner-stone publication by Bastiaannet et

Read More »

Radboud university medical center and Quirem Medical sign cooperation agreement

Radboud university medical center and Quirem Medical today signed an agreement for joint research. The agreement includes several existing and future projects based on small radioactive spheres (holmium-166 microspheres). Enhanced cooperation should improve the treatment of cancer patients and stimulate research into new applications. “Radboud university medical center strives for

Read More »

QuiremScout® superior in predicting intrahepatic dose distribution

In their study, Smits et al. showed that QuiremScout® is a superior predictor of  intrahepatic dose distribution compared to Tech-99m-MAA. The results of their study were published online on the 9th of August 2019 in the European Journal of Nuclear Medicine and Molecular Imaging. With individualized treatment planning becoming increasingly

Read More »

First clinical case using the McMaster Nuclear Reactor

McMaster University and Quirem Medical announce the first clinical case using the McMaster Nuclear Reactor Deventer (The Netherlands), Hamilton (Canada), 6th of June 2019 McMaster University and Quirem Medical announce the first clinical case using the McMaster Nuclear Reactor (MNR) for the irradiation of QuiremSpheres®.  QuiremSpheres®, the next generation of

Read More »

The first QuiremScout cases successfully performed

The first QuiremScout® cases have been successfully performed by clinical teams in Dresden and Pisa last week. We congratulate the clinical teams, and everyone involved! QuiremScout® is the first and only CE-marked SIRT work-up product that consists of the same particle as the therapeutic microspheres. It improves the accuracy of

Read More »